Gilead Moves To Block Harvoni Infringer In India
This article was originally published in Scrip
Executive Summary
Gilead Sciences has moved court to block an alleged copy of its blockbuster hepatitis C treatment, Harvoni (sofosbuvir/ledipasvir), in India which it believes not only wrongly rides on the brand name but may also not have the requisite regulatory approvals.